Müller, V., Hörner, M., Thill, M., Banys-Paluchowski, M., Schmatloch, S., Fasching, P. A., . . . Hartkopf, A. D. Real-world utilization of aromatase inhibitors, tamoxifen, and ovarian function suppression in premenopausal patients with early hormone receptor-positive, HER2-negative breast cancer with increased recurrence risk. Elsevier.
Chicago Style (17th ed.) CitationMüller, Volkmar, et al. Real-world Utilization of Aromatase Inhibitors, Tamoxifen, and Ovarian Function Suppression in Premenopausal Patients with Early Hormone Receptor-positive, HER2-negative Breast Cancer with Increased Recurrence Risk. Elsevier.
MLA (9th ed.) CitationMüller, Volkmar, et al. Real-world Utilization of Aromatase Inhibitors, Tamoxifen, and Ovarian Function Suppression in Premenopausal Patients with Early Hormone Receptor-positive, HER2-negative Breast Cancer with Increased Recurrence Risk. Elsevier.